Skip to main content
Top
Published in: BMC Musculoskeletal Disorders 1/2009

Open Access 01-12-2009 | Research article

Disease activity level, remission and response in established rheumatoid arthritis: Performance of various criteria sets in an observational cohort, treated with anti-TNF agents

Authors: Anders Gülfe, Daniel Aletaha, Tore Saxne, Pierre Geborek

Published in: BMC Musculoskeletal Disorders | Issue 1/2009

Login to get access

Abstract

Background

Most composite indices of disease activity and response criteria in RA have been validated and compared in clinical trials rather than routine care. We therefore wanted to compare the performance of the DAS28, SDAI and CDAI activity indices, their activity states, their response criteria, and also compare with the ACR response criteria in an observational clinical setting.

Methods

Agreement between the criteria sets was investigated using κ statistics in a non-randomized cohort of 1789 RA patients from southern Sweden, starting their first course of anti-TNF-treatment. Mean disease duration was 12 years. Completer analysis was used.

Results

Agreement between high, moderate and low activity states was moderate or substantial, with κ = 0.5 or better for all criteria. Agreement between SDAI and CDAI disease states was > 90% in these categories with κ > 0.8. DAS28 original and modified cut point remission had good agreement (κ = 0.91). Agreement between responses was substantial at the overall/ACR20 level (about 95%, κ = 0.7 or better) for all criteria. By contrast, agreement was poor between moderate and high level responses.

Conclusion

Disease activity states according to the various indices perform similarly and show substantial agreement at all levels except remission. Agreement between SDAI and CDAI states is excellent. Response criteria, applied at the individual patient level, are hard to interpret and show poor agreement, except at the lowest level of response. Thus, they should not be applied uncritically in clinical practice.
Appendix
Available only for authorised users
Literature
2.
go back to reference Smolen PJS: A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003, 42 (2): 244-57. 10.1093/rheumatology/keg072.CrossRef Smolen PJS: A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003, 42 (2): 244-57. 10.1093/rheumatology/keg072.CrossRef
3.
go back to reference Aletaha DNV, Stamm T, Uffmann M, Pflugbeil S, Machold K, Smolen JS: Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Research & Therapy. 2005, 7: R796-R806. 10.1186/ar1740.CrossRef Aletaha DNV, Stamm T, Uffmann M, Pflugbeil S, Machold K, Smolen JS: Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Research & Therapy. 2005, 7: R796-R806. 10.1186/ar1740.CrossRef
4.
go back to reference Zink A: Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum. 2006, 54 (11): 3399-407. 10.1002/art.22193.CrossRefPubMed Zink A: Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum. 2006, 54 (11): 3399-407. 10.1002/art.22193.CrossRefPubMed
5.
go back to reference A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. Arthritis Rheum. 2007, 57 (2): 193-202. 10.1002/art.22552. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. Arthritis Rheum. 2007, 57 (2): 193-202. 10.1002/art.22552.
6.
go back to reference van Gestel AM: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996, 39 (1): 34-40. 10.1002/art.1780390105.CrossRefPubMed van Gestel AM: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996, 39 (1): 34-40. 10.1002/art.1780390105.CrossRefPubMed
7.
go back to reference Felson DT: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995, 38 (6): 727-35. 10.1002/art.1780380602.CrossRefPubMed Felson DT: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995, 38 (6): 727-35. 10.1002/art.1780380602.CrossRefPubMed
8.
go back to reference Gulfe A, Geborek P, Saxne T: Response criteria for rheumatoid arthritis in clinical practice: how useful are they?. Ann Rheum Dis. 2005, 64 (8): 1186-9. 10.1136/ard.2004.027649.CrossRefPubMedPubMedCentral Gulfe A, Geborek P, Saxne T: Response criteria for rheumatoid arthritis in clinical practice: how useful are they?. Ann Rheum Dis. 2005, 64 (8): 1186-9. 10.1136/ard.2004.027649.CrossRefPubMedPubMedCentral
9.
go back to reference Geborek P, Saxne T: Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis. Rheumatology (Oxford). 2000, 39 (10): 1159-61. 10.1093/rheumatology/39.10.1159.CrossRef Geborek P, Saxne T: Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis. Rheumatology (Oxford). 2000, 39 (10): 1159-61. 10.1093/rheumatology/39.10.1159.CrossRef
10.
go back to reference Viera AJ, Garrett JM: Understanding interobserver agreement: the kappa statistic. Fam Med. 2005, 37 (5): 360-3.PubMed Viera AJ, Garrett JM: Understanding interobserver agreement: the kappa statistic. Fam Med. 2005, 37 (5): 360-3.PubMed
11.
go back to reference Landis JRKG: The measurement of observer agreement for categorical data. Biometrics. 1977, 33: 159-174. 10.2307/2529310.CrossRefPubMed Landis JRKG: The measurement of observer agreement for categorical data. Biometrics. 1977, 33: 159-174. 10.2307/2529310.CrossRefPubMed
12.
go back to reference Hyrich KL: Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2006, 45 (12): 1558-65. 10.1093/rheumatology/kel149.CrossRef Hyrich KL: Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2006, 45 (12): 1558-65. 10.1093/rheumatology/kel149.CrossRef
13.
go back to reference Kristensen LE, Kapetanovic MC, Gülfe A, Söderlin M, Saxne T, Geborek P: Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford). 2008, 47 (4): 495-9. 10.1093/rheumatology/ken002.CrossRef Kristensen LE, Kapetanovic MC, Gülfe A, Söderlin M, Saxne T, Geborek P: Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford). 2008, 47 (4): 495-9. 10.1093/rheumatology/ken002.CrossRef
14.
go back to reference Aletha D, S J: The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005, 23 (5 Suppl 39): S100-S108. Aletha D, S J: The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005, 23 (5 Suppl 39): S100-S108.
15.
go back to reference Aletaha D: Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005, 52 (9): 2625-36. 10.1002/art.21235.CrossRefPubMed Aletaha D: Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005, 52 (9): 2625-36. 10.1002/art.21235.CrossRefPubMed
16.
go back to reference Wolfe F: Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. Arthritis Rheum. 2007, 57 (6): 935-42. 10.1002/art.22895.CrossRefPubMed Wolfe F: Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. Arthritis Rheum. 2007, 57 (6): 935-42. 10.1002/art.22895.CrossRefPubMed
Metadata
Title
Disease activity level, remission and response in established rheumatoid arthritis: Performance of various criteria sets in an observational cohort, treated with anti-TNF agents
Authors
Anders Gülfe
Daniel Aletaha
Tore Saxne
Pierre Geborek
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2009
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/1471-2474-10-41

Other articles of this Issue 1/2009

BMC Musculoskeletal Disorders 1/2009 Go to the issue